iBio (IBIO) Other Operating Expenses (2013 - 2024)

iBio (IBIO) posted quarterly Other Operating Expenses of $1.0 million for Q1 2024, up 158.62% quarter-over-quarter from -$1.7 million in Q2 2023.

iBio (IBIO) Other Operating Expenses (2013 - 2024) Analysis & Trends

iBio (IBIO) has reported Other Operating Expenses for 10 consecutive years, with $1.0 million the latest figure, recorded in Q1 2024.

In Q1 2024, Other Operating Expenses changed N/A year-over-year to $1.0 million; the TTM figure through Dec 2024 stood at $1.0 million (up 158.62% YoY), while the FY2024 annual figure was $1.0 million, changed N/A from the prior year.
Other Operating Expenses improved to $1.0 million in Q1 2024 per IBIO's latest filing, from -$1.7 million in the prior quarter.
Across five years, Other Operating Expenses topped out at $5.7 million in Q4 2022 and bottomed at -$1.7 million in Q2 2023.
Historically, Other Operating Expenses has averaged $596750.0 across 5 years, with a median of -$182500.0 in 2020.
Annual changes were most pronounced in 2022 — Other Operating Expenses soared 9385.25% — and 2023, when it slumped 147.89%.
iBio's Other Operating Expenses stood at -$177000.0 in 2020, then soared by 65.54% to -$61000.0 in 2021, then jumped by 9385.25% to $5.7 million in 2022, then plunged by 130.12% to -$1.7 million in 2023, then soared by 158.62% to $1.0 million in 2024.
Business Quant data shows IBIO's Other Operating Expenses at $1.0 million in Q1 2024, -$1.7 million in Q2 2023, and $5.7 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	iBio	172.22 Mn	172.22 Mn	-

Download Data